Sandrine Vendeville

Experienced drug hunter with proven scientific, strategic and organizational leadership to deliver high quality clinical candidates. Highly passionate and enthusiastic about drug discovery and medicinal chemistry. Results-driven and out-of-the-box thinker, with strong problem-solving skills. Preference for fast-paced, challenging and multi-cultural environment. Co-inventor of Simeprevir, approved for the treatment of HCV. As co-inventor and project leader, delivered multiple assets in clinical stage• TMC-647055 (novel HCV NNI that reached phase 2b), whose combination with Simeprevir in a QD regimen led to high SVR in patients. • JNJ-53718678, a fusion inhibitor for the treatment of RSV, currently in phase 3• ALG-184, a potentially best-in-class CAM for the treatment of HBV, currently in phase 2.Extensive knowledge and demonstrated success in optimization of physicochemical properties, pharmacokinetics and metabolism, and toxicity (ADMET) of drug candidates.Medchem and synthetic chemistry experience in peptido-mimetics, war-head containing irreversible/tight binding inhibitors, macrocycles, natural products, heterocycles and prodrugs.Responsible for IP strategy, creation, protection and expansion in collaboration with IP team.Team member of Due diligence and joint steering committee.>50 patents and publications including book chapter.Recipient of 2 JNJ Philip B. Hofmann Awards for outstanding scientific achievement, 1 JNJ research leadership award and two Aligos 101st awards for outstanding scientific contribution.